Clinical expression and antigenic profiles of a Plasmodium vivax vaccine candidate: merozoite surface protein 7 (PvMSP-7)

Table 2 Summary statistics of RNA preparation, RNA sequencing, read mapping to the human GRCh37 and P. vivax P01 genomes, and sequence coverage, for 10 clinical isolates from vivax malaria patients taken from two regions: Ubon Ratchathani (UBT; North-East) and Yala (YL; South)

Isolate		Total RNA (ng)	RNA integrity number (RIN)	Total read pairs^a	Pair reads mapped to human	Percentage of reads mapped to human	Pair reads mapped to P. vivax	Percentage of reads mapped to P. vivax	Mean sequence coverage
1	UBT3086	585.2	2	29,157,609	22,771,884	78.10	346,899	1.20	1.82
2	UBT3087	392	2.4	36,549,438	29,392,764	80.42	977,753	2.68	17.67
3	UBT3089	1498	2.3	30,083,802	23,272,992	77.36	3,035,144	10.09	78.52
4	UBT3090	719.6	2.3	30,397,809	22,226,523	73.12	3,267,128	10.75	17.59
5	UBT3091	504	2.3	28,550,673	18,312,289	64.14	6,388,456	22.38	42.07
6	YL3111	627.2	2.3	29,500,938	26,039,174	88.27	580,181	1.97	3.18
7	YL3112	1005.2	2.3	32,578,915	27,732,216	85.12	913,421	2.80	4.95
8	YL3113	280	2	26,853,921	21,654,627	80.64	209,249	0.78	1.07
9	YL3114	1470	2.8	31,860,822	27,764,327	87.14	350,337	1.10	1.88
10	YL3115	641.2	2.5	32,987,343	24,102,143	73.05	3,469,628	10.52	20.13

ISSN: 1475-2875